Browse GIGYF2

Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF02213 GYF domain
Function

Key component of the 4EHP-GYF2 complex, a multiprotein complex that acts as a repressor of translation initiation (PubMed:22751931). In 4EHP-GYF2 the complex, acts as a factor that bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay (By similarity). May act cooperatively with GRB10 to regulate tyrosine kinase receptor signaling, including IGF1 and insulin receptors (PubMed:12771153).

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0001894 tissue homeostasis
GO:0006417 regulation of translation
GO:0007093 mitotic cell cycle checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007626 locomotory behavior
GO:0007631 feeding behavior
GO:0008344 adult locomotory behavior
GO:0009791 post-embryonic development
GO:0010608 posttranscriptional regulation of gene expression
GO:0010948 negative regulation of cell cycle process
GO:0017148 negative regulation of translation
GO:0021510 spinal cord development
GO:0021515 cell differentiation in spinal cord
GO:0021517 ventral spinal cord development
GO:0021522 spinal cord motor neuron differentiation
GO:0021953 central nervous system neuron differentiation
GO:0030534 adult behavior
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0035264 multicellular organism growth
GO:0044708 single-organism behavior
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0048009 insulin-like growth factor receptor signaling pathway
GO:0048871 multicellular organismal homeostasis
GO:0048872 homeostasis of number of cells
GO:0048873 homeostasis of number of cells within a tissue
GO:0050879 multicellular organismal movement
GO:0050881 musculoskeletal movement
GO:0050885 neuromuscular process controlling balance
GO:0050905 neuromuscular process
GO:0060249 anatomical structure homeostasis
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005913 cell-cell adherens junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GIGYF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GIGYF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.44; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GIGYF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0180.939
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3370.847
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2170.868
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1160.57
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0070.998
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2710.93
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1480.697
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0910.959
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2110.916
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3530.782
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0050.591
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.010.843
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GIGYF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.48.5-1.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GIGYF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GIGYF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GIGYF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GIGYF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GIGYF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GIGYF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGIGYF2
NameGRB10 interacting GYF protein 2
Aliases KIAA0642; GYF2; GYF domain containing 2; PERQ2; PERQ3; TNRC15; PERQ amino acid rich, with GYF domain 2; PERQ ......
Chromosomal Location2q37.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GIGYF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.